MLYS Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 35% planned / 65% discretionary
Largest single sale: $3.0M.
Where they traded
Last open-market purchase: March 30, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Slingsby Brian Taylor | Director | Sell | 104,320 | $28.81 | $3.0M | 7,805,718 −1.3% of holding | |
| Warren Eric | Chief Commercial Officer | Sell 10b5-1 | 7,438 | $28.12 | $209.1K | 38,400 −16.2% of holding | |
| Warren Eric | Chief Commercial Officer | Sell 10b5-1 | 7,437 | $25.98 | $193.2K | 38,400 −16.2% of holding | |
| Rodman David Malcom | Chief Medical Officer | Sell 10b5-1 | 2,170 | $27.09 | $58.8K | 51,384 −4.1% of holding | |
| Warren Eric | Chief Commercial Officer | Sell 10b5-1 | 7,438 | $26.87 | $199.9K | 38,400 −16.2% of holding | |
| Rodman David Malcom | Chief Medical Officer | Sell 10b5-1 | 416 | $26.53 | $11.0K | 51,384 −0.8% of holding | |
| Rodman David Malcom | Chief Medical Officer | Sell 10b5-1 | 6,349 | $26.61 | $169.0K | 51,384 −11% of holding | |
| Rodman David Malcom | Chief Medical Officer | Sell 10b5-1 | 14,058 | $27.58 | $387.7K | 57,733 −19.6% of holding | |
| Congleton Jon | Chief Executive Officer | Sell 10b5-1 | 10,700 | $27.24 | $291.4K | 603,621 −1.7% of holding | |
| Rodman David Malcom | Chief Medical Officer | Sell 10b5-1 | 2,171 | $30.30 | $65.8K | 57,733 −3.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.